Based on these results, secreted BAG3 (and its receptor IFITM-2) represent potential clinical candidate molecules for the treatment of pancreatic cancer (development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer). Here, BAG3 is linked to familial pancreatic carcinoma.